Quest PharmaTech: Top 25 Undervalued TSX Venture Exchange Stocks (QPT)
Quest PharmaTech is now ranked among the top 25 undervalued stocks listed on the TSX Venture Exchange.
- A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
- Valuation methodology provided by Stockcalc (see below)
- Small, micro and nano group market capitalization (<10B)
Stocks in this category are held primarily for capital appreciation and/or dividends.
TSX Venture Exchange focusses on earlier-stage companies looking to access capital to fund growth – especially in Canada's rich natural-resource sectors. Many companies are also dually-listed in US and international markets.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap ($M) | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| JNH | Jack Nathan Medical | 0.01 | 0.02 | 0.02 (390.0%) | 30388 | 0.4 | 0.0 | 0.0 |
| FWTC | Forward Water Techs | 0.04 | 0.19 | 0.15 (367.6%) | 4476 | 0.8 | 0.0 | 0.0 |
| POR | Portofino Resources | 0.01 | 0.02 | 0.02 (361.7%) | 61266 | 0.9 | 0.0 | 0.0 |
| TR | Troubadour Resources | 0.03 | 0.11 | 0.08 (253.1%) | 76605 | 1.2 | 0.0 | 0.0 |
| Q | Quetzal Copper | 0.04 | 0.12 | 0.09 (250.2%) | 166970 | 1.4 | 0.0 | 0.0 |
| PCLO | PharmaCielo | 0.04 | 0.15 | 0.11 (239.7%) | 76738 | 7.7 | 0.0 | 0.0 |
| QPT | Quest PharmaTech | 0.04 | 0.12 | 0.08 (229.5%) | 11830 | 5.9 | 0.0 | 0.0 |
| SCAN | Liberty Defense Holdings | 0.29 | 0.85 | 0.56 (194.1%) | 219611 | 5.0 | 0.0 | 0.0 |
| KLX | Carbon Done Right | 0.01 | 0.03 | 0.02 (185.3%) | 187227 | 0.9 | 0.0 | 0.0 |
| NAV | Navco Pharmaceuticals | 0.01 | 0.01 | 0.01 (166.0%) | 3633 | 0.0 | 0.0 | 0.0 |
| IFR | Intl Frontier Resources | 0.03 | 0.08 | 0.05 (165.3%) | 3996 | 0.9 | 0.0 | 0.0 |
| ARJN | Aranjin Resources | 0.05 | 0.13 | 0.08 (163.0%) | 2955 | 0.6 | 0.0 | 0.0 |
| STUD | Stallion Uranium | 0.14 | 0.37 | 0.23 (162.9%) | 26319 | 4.0 | 0.0 | 0.0 |
| OYL | CGX Energy | 0.08 | 0.21 | 0.13 (158.8%) | 29467 | 27.1 | 0.0 | 0.0 |
| MAX | MAX Resource | 0.04 | 0.12 | 0.07 (156.3%) | 45821 | 8.0 | 0.0 | 0.0 |
| DIA | Margaret Lake Diamonds | 0.10 | 0.26 | 0.16 (155.2%) | 376 | 0.5 | 0.0 | 0.0 |
| MNX | Manitex Capital | 0.07 | 0.19 | 0.11 (151.2%) | 1.0 | 0.0 | 0.0 | |
| NSU | North Shore Uranium | 0.03 | 0.08 | 0.05 (150.2%) | 33298 | 1.1 | 0.0 | 0.0 |
| BMET | BeMetals | 0.04 | 0.08 | 0.05 (141.7%) | 49186 | 6.9 | 0.0 | 0.0 |
| ABR | Arbor Metals | 0.21 | 0.50 | 0.29 (138.6%) | 136821 | 19.0 | 0.0 | 21.0 |
| PUL | Pulse Oil | 0.01 | 0.02 | 0.01 (138.5%) | 1677 | 6.2 | 0.0 | 0.0 |
| DEAL | Playgon Games | 0.01 | 0.02 | 0.01 (136.9%) | 40503 | 3.0 | 0.0 | 0.0 |
| ENEV | Enerev5 Metals | 0.01 | 0.01 | 0.01 (136.6%) | 4809 | 1.2 | 0.0 | 0.0 |
| VRB | Vanadiumcorp Resource | 0.12 | 0.28 | 0.16 (135.7%) | 8772 | 1.1 | 0.0 | 0.0 |
| SR | Strategic Resources | 0.46 | 1.08 | 0.62 (134.6%) | 5555 | 3.5 | 0.0 | 0.0 |
All data provided as of June 15, 2025.
The list is sorted by stocks with the greatest percentage difference between valuation and price.
Quest PharmaTech
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.
Quest PharmaTech is listed under QPT on the TSX Venture Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.
Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:
- Discounted Cash Flow (DCF)
- Price & Other Comparables
- Multiples
- Adjusted Book Value (ABV)
- Analyst Consensus
Artificial Intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
